3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
38
Carcinoma, Non-Small-Cell Lung
23
Stomach Neoplasms
19
Nasopharyngeal Carcinoma
19
Triple Negative Breast Neoplasms
18
Esophageal Squamous Cell Carcinoma
17
Esophageal Neoplasms
16
Breast Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
13
Colorectal Neoplasms
11
Uterine Cervical Neoplasms
10
Pancreatic Neoplasms
8
Sarcoma
6
Recurrence
6
Neoplasm Metastasis
6
Melanoma
6
Liver Neoplasms
6
Cholangiocarcinoma
6
Lung Neoplasms
5
Hodgkin Disease
5
Biliary Tract Neoplasms
5
Osteosarcoma
4
Neoplasms
4
Locally Advanced Gastric Cancer
4
Advanced Gastric Cancer
4
Rectal Neoplasms
3
Nasopharyngeal Neoplasms
3
Glioblastoma
3
Gestational Trophoblastic Disease
3
Urinary Bladder Neoplasms
2
Interventions
pembrolizumab
4
Nivolumab
3
toripalimab
2
sintilimab
2
Neoadjuvant Therapy
2
Celecoxib
2
tislelizumab
1
spartalizumab
1
relatlimab
1
regorafenib
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
denileukin diftitox
1
danvatirsen
1
camrelizumab
1
avelumab
1
atezolizumab
1
XELOX
1
Taxes
1
Surgical Procedures, Operative
1
Radiation Dose Hypofractionation
1
Paclitaxel
1
Megestrol Acetate
1
Medroxyprogesterone Acetate
1
Ipilimumab
1
Induction Chemotherapy
1
Immunotherapy
1
Immunoglobulin G
1
Immune Checkpoint Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Turcot syndrome
×
camrelizumab
×
Clear all
NCT06215677
2025-09-05
NITDC
Peking Union Medical College Hospital
Phase NA
Recruiting
18 enrolled